Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Cancer Clinical Trial

Official title:

A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00288431
• Other study ID #: 8669-015
• Secondary ID: AP23573-05-107
• Status: Completed
• Phase: Phase 1
• First received: February 6, 2006
• Last updated: July 21, 2015
• Start date: February 2006
• Est. completion date: July 2008

Study information

• Verified date: July 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is designed to determine the safety, tolerability and maximum tolerated dose of Oral AP23573 in combination with Doxorubicin

Description:

The primary objective is to determine the maximum tolerated dose (MTD) of AP23573 in combination with doxorubicin, to characterize the safety profile of AP23573 in combination with doxorubicin, and to examine the pharmacokinetics of AP23573 and doxorubicin when given in combination to patients with advanced malignancies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years with a histological/cytological diagnosis of advanced tumor, preferentially breast, sarcoma, ovarian, endometrial or other tumor types for which treatment with anthracycline therapy is indicated

• Prior cumulative doxorubicin exposure less than 400 mg/m2

• An ECOG performance status of 0 or 1

• Adequate cardiovascular function

• Measurable disease according to modified RECIST criteria

• Adequate hematological, renal and hepatic functions

• Able to understand and give voluntary written informed consent

Exclusion Criteria:

• Women who are pregnant or lactating

• Presence of active brain metastases. Patients with treated brain metastases will be eligible if they are on a stable dose of corticosteroids or are without change in brain disease status for at least 4 weeks following related therapy (e.g., whole brain radiation, surgery)

• Prior treatment with CCI-779, rapamycin, or any other mTOR inhibitor

• Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of AP23573; the interval is = 2 weeks for signal transduction inhibitors with a half-life known to be <24 hours, and is = 6 weeks for nitrosourea or mitomycin. Exception: Concurrent treatment with LHRH agonists is allowed for patients with prostate cancer.

• Ongoing toxicity associated with prior anticancer therapy other than alopecia and = Grade 1 peripheral neuropathy by NCI toxicity criteria

• Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)

• Known or suspected hypersensitivity to any excipient contained in the study drug

• Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)

• Significant uncontrolled cardiovascular disease

• Any active infection requiring prescribed intervention

• Any other concurrent illness which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug

• Any pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption

• Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for = 2 weeks prior to first planned dose of study drug

• Concurrent treatment with medications that induce or inhibit cytochrome P450 (CYP3A)

• Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of AP23573

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer
• Sarcoma

Intervention

Drug:
• ridaforolimus
Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
• Doxorubicin
administered at 60 mg/m2 intravenously every 3 weeks

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.	Ariad Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	determine the maximum tolerated dose (MTD) of oral AP23573 in combination with doxorubicin		Duration of study	Yes
Secondary	Describe the antitumor activity of the study drug combination for each dosing schedule		Duration of study	No
Secondary	examine the pharmacokinetics of oral AP23573 and doxorubicin when given in combination		Duration of study	No
Secondary	Examine pharmacodynamic characteristics of AP23573 for those patients enrolled into the expanded MTD cohorts only		Duration of study	No